GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Janux Therapeutics Inc (NAS:JANX) » Definitions » Future 3-5Y Total Revenue Growth Rate

JANX (Janux Therapeutics) Future 3-5Y Total Revenue Growth Rate : N/A (As of Jan. 19, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Janux Therapeutics Future 3-5Y Total Revenue Growth Rate?

Future 3-5Y Total Revenue Growth Rate is the average growth rate of total revenue estimates over a 3-year to 5-year period.

As of today, Janux Therapeutics's Future 3-5Y Total Revenue Growth Rate is N/A.

Competitive Comparison of Janux Therapeutics's Future 3-5Y Total Revenue Growth Rate

For the Biotechnology subindustry, Janux Therapeutics's Future 3-5Y Total Revenue Growth Rate, along with its competitors' market caps and Future 3-5Y Total Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Janux Therapeutics's Future 3-5Y Total Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Janux Therapeutics's Future 3-5Y Total Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Janux Therapeutics's Future 3-5Y Total Revenue Growth Rate falls into.


Janux Therapeutics  (NAS:JANX) Future 3-5Y Total Revenue Growth Rate Explanation

Future 3-5Y Total Revenue Growth Rate is the growth rate of total revenue estimates over a 3-year to 5-year period. This data is provided directly by our trusted data vendors Refinitiv or Morningstar.

In situations where both vendors do not directly provide the growth rate data, we use the most recent annual revenue for the current year and estimated future revenue figures provided by the vendor to calculate the growth rate. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average total revenue estimates growth rate.

Janux Therapeutics Future 3-5Y Total Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Janux Therapeutics's Future 3-5Y Total Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Janux Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Janux Therapeutics Inc (NAS:JANX) » Definitions » Future 3-5Y Total Revenue Growth Rate
Comparable Companies
DNLI XENE CRSP RYTM RXRX MRUS FOLD ZLAB PTCT MLTX VRTX ASX:CSL REGN XKRX:207940 XBRU:UCB XBRU:ARGX ALNY BNTX XKRX:068270 BGNE
Traded in Other Exchanges
N/A
Address
10955 Vista Sorrento Parkway, Suite 200, San Diego, CA, USA, 92130
Website
https://www.januxrx.com
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to treat patients suffering from cancer.
Executives
David Alan Campbell director, officer: Chief Executive Officer C/O JANUX THERAPEUTICS, INC., 11099 N. TORREY PINES ROAD, SUITE 290, LA JOLLA CA 92037
Ra Capital Healthcare Fund Lp director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Avalon Ventures Xi, L.p. 10 percent owner 1134 KLINE STREET, LA JOLLA CA 92037
Andrew Hollman Meyer officer: Chief Business Officer C/O JANUX THERAPEUTICS, INC., 11099 N. TORREY PINES ROAD, SUITE 290, LA JOLLA CA 92037
Jay Lichter director, 10 percent owner C/O ARATANA THERAPEUTICS, INC., 11400 TOMAHAWK CREEK PARKWAY, SUITE 340, LEAWOOD KS 66211
Tighe Reardon 10 percent owner, officer: Acting Chief Financial Officer C/O SYNTHORX, INC., 11099 NORTH TORREY PINES ROAD, SUITE 190, LA JOLLA CA 92037
Ra Capital Nexus Fund Ii, L.p. director 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Charles M. Winter officer: Chief Technical Officer C/O JANUX THERAPEUTICS, INC., 10955 VISTA SORRENTO PARKWAY, SUITE 200, SAN DIEGO CA 92130
Winston Kung director C/O PMV PHARMACEUTICALS, INC., 8 CLARKE DRIVE, SUITE 3, CRANBURY NJ 08512
Byron Robinson officer: Chief Strategy Officer C/O JANUX THERAPEUTICS, INC., 11099 N. TORREY PINES ROAD, SUITE 290, LA JOLLA CA 92037
Orbimed Advisors Llc director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Peter A. Thompson director C/O ANTHERA PHARMACEUTICALS, INC., 25801 INDUSTRIAL BOULEVARD, SUITE B, HAYWARD CA 94545
Orbimed Capital Gp Viii Llc director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022-4629
Orbimed Genesis Gp Llc director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Gp Vii Llc director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022